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Abstract 
Background: Transfusion thresholds for acute upper gastrointestinal bleeding 
(AUGIB) are controversial. To date there is only one relevant study, a single centre 
trial which reported reduced mortality with restrictive red blood cell (RBC) 
transfusion. Pragmatic studies are needed to confirm or refute this finding. We aimed 
to assess whether a multicentre cluster randomised trial was a feasible method of 
addressing this uncertainty. 
 
Methods: TRIGGER was a pragmatic, open-label cluster randomised trial conducted 
in six university hospitals in the United Kingdom. Hospitals were randomly assigned 
(1:1) by a computer generated randomisation sequence (block size 6, without 
stratification) to either a restrictive (transfusion when haemoglobin (Hb) <80g/L) or 
liberal (transfusion when Hb <100g/L) RBC transfusion policy. All new adult 
presentations with AUGIB were eligible for enrolment, regardless of co-morbidity. 
Neither patients nor investigators were masked to treatment allocation. Main 
feasibility outcomes were recruitment rate, protocol adherence, Hb levels and RBC 
exposure. Main exploratory clinical outcomes were further bleeding and mortality at 
day 28. This study is registered with ClinicalTrials.gov (number NCT02105532) and 
ISRCTN (number 85757829). 
 
 
Findings: Between September 2012 and March 2013, 1600 of 1667 (96%) 
participants were eligible and 936 of 1660 (59%) eligible participants were enrolled 
across six hospitals (three restrictive, 403 participants; three liberal, 533 
participants). Despite some baseline imbalances, Rockall and Blatchford risk scores 
were identical between policies. Protocol adherence was 96% in the restrictive policy 
vs. 83% in the liberal policy) (difference 14%, 95% CI 7% to 21%). For the 
restrictive policy, Hb at discharge was lower (difference for patients with Hb<120 g/L 
-7·0; 95% CI -14·0 to 0.0) and fewer patients received RBCs (difference -13%, 95% 
CI -36 to 12%) with a mean of 0·8 (-1·9 to 0·3) fewer RBC units transfused. There 
was no significant difference in clinical outcomes: 28-day further bleeding, 5% (13 of 
257) restrictive vs. 9% (31 of 383) liberal (difference -3·7%, 95% CI -12·2 to 4·8%); 
28-day mortality, 5% (14 of 257) restrictive vs. 7% (25 of 383) liberal (difference -
1·3%, 95% CI -8.0 to 5.5%). 
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Interpretation: Using a cluster randomised design led to rapid recruitment, high 
protocol adherence, separation in the degree of anaemia between groups and 
reduction in RBC transfusion in the restrictive policy. A larger cluster-randomised trial 
to assess the effectiveness of transfusion strategies for AUGIB is both feasible and 
essential to conduct before clinical practice guidelines change to recommend 
restrictive transfusion for all patients with AUGIB. 
 
Funding: NHS Blood and Transplant R&D, grant 10-09-CSU.  
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Introduction 
Acute Upper Gastrointestinal Bleeding (AUGIB) accounts for 70,000 admissions each 
year to UK hospitals (1) and 11% of all red blood cells (RBC) transfused in England 
(2). Despite being the most common single indication for RBC transfusion, the 
optimum threshold for transfusion is uncertain (3). Randomised trials in other 
critically ill cohorts have demonstrated that thresholds for transfusion can be safely 
lowered without adversely affecting outcomes (4-6). It is unclear whether a 
restrictive approach to transfusion can safely be extrapolated to older patients with 
acute bleeding or cardiovascular disease (7-10), which is particularly relevant to 
AUGIB where the burden of co-morbidity is high (3, 11).  
 
Cohort studies suggest associations between RBC transfusion after AUGIB and 
adverse clinical outcomes (12-13). A recent single-centre randomised controlled trial 
(RCT) conducted over six years in a specialist gastrointestinal bleeding unit in 
Barcelona reported reduced mortality and rebleeding through implementation of 
restrictive transfusion for AUGIB (14). However, it is unlikely that these results are 
generalisable to routine clinical practice given the exclusion of patients with major 
cardiovascular comorbidity, stringent processes of care and differing case mix (3). A 
large, pragmatic, multicentre trial is essential to either confirm or refute these 
findings before clinical practice guidelines are changed worldwide. Since AUGIB is a 
medical emergency, can require early transfusion and involves numerous care-
providers, conducting a trial which requires adherence to transfusion strategies 
across multiple centres would be challenging.  
 
We conducted the Transfusion in Gastrointestinal Bleeding Trial (TRIGGER) to 
evaluate whether it was feasible and safe to implement a restrictive versus liberal 
RBC transfusion policy for AUGIB in routine clinical practice through cluster 
randomisation, as well as an exploratory analysis of the major clinical consequences, 
enrolling all new adult admissions regardless of their co-morbidity or age. 
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Methods 
Study design and participants 
TRIGGER was a pragmatic, cluster randomised trial of a restrictive versus liberal RBC 
transfusion policy in adults with AUGIB in the UK, conducted to inform the feasibility 
and design of a phase 3 trial. Due to the need for immediate implementation of a 
RBC transfusion policy from first presentation until discharge, across several specialty 
groups in different clinical areas of a hospital, we chose a cluster design to simplify 
intervention delivery and reduce contamination between policies. A feasibility trial 
was considered essential to determine whether clinician behaviour could be changed 
on a hospital wide scale and to assess potential for selection bias or outcome 
reporting bias, given the open label nature of the study, whereby all clinicians, 
patients and outcome assessors were aware of the transfusion policy, which could 
lead to selection bias or outcome reporting bias. A rationale and methodology paper 
has been published (15) and the full protocol is available online (16).  
 
Hospitals were eligible if they had >20 AUGIB admissions monthly; >400 adult beds; 
24 hour endoscopy; on-site access to intensive care and surgery; and willing to be 
randomised to and implement a transfusion policy for all new AUGIB admissions . 
Eligible participants were new presentations with AUGIB aged ≥18 years; the only 
exclusion was exsanguinating haemorrhage for which objective guidance criteria 
were provided (web appendix page 1). Written informed consent was sought from 
individual participants or their representative for use of routine hospital records and 
telephone follow up at day 28. Ethical approval was granted in England and 
Scotland. 
 
Randomisation and Masking  
Centres were randomised to a transfusion policy using a random permuted block of 
six (three hospitals per policy), without stratification or matching. Participants were 
identified from Emergency Departments and Acute Admissions Units between the 3rd 
September 2012 and 1st March 2013.  
 
Procedures 
In the restrictive policy, participants were eligible for RBC transfusion when the 
haemoglobin concentration (Hb) fell below 80 g/L, with a post-transfusion target Hb 
of 81-100 g/L. In the liberal policy, patients were eligible for transfusion when Hb fell 
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below 100 g/L, with a target post-transfusion Hb of 101-120 g/L. These thresholds 
were informed by UK transfusion practice during the study design (15). The number 
of RBC units transfused and the timing of repeat Hb measurements was per clinician 
discretion. All clinicians could deviate from the policy, but were approached to 
document the reason. In keeping with the pragmatic design, no other aspects of care 
were protocol driven, although clinicians were encouraged to follow evidence-based 
guidelines (17-18). 
 
A lead clinician championed the study at each site, supported by a co-investigator 
from an allied acute specialty. A multi-faceted approach was used to implement the 
policy including the daily presence of a research nurse in acute areas, regular 
attendance at medical and nursing handovers in acute areas to reinforce the policy, 
departmental and grand round presentations, posters, regular email reminders and a 
flagging system in transfusion laboratories to remind doctors and transfusion 
laboratory scientific staff of the policy whenever a transfusion request for AUGIB 
occurred. 
 
 
Outcome measures  
Feasibility and clinical outcome measures were collected. Definitions are available in 
the online protocol (16). Feasibility outcomes included recruitment rate, adherence to 
the transfusion policy (overall, per patient, and per Hb count), Hb and RBC exposure 
and evidence of selection bias. We measured Hb levels (over the first seven days, 
over the entire follow-up period, and prior to discharge), the proportion of patients 
receiving at least one RBC transfusion and the number of units transfused. Clinical 
outcomes were further bleeding, thromboembolic events, and infection (in-hospital 
and at day 28, with day 28 being the main analysis time point). Mortality, serious 
adverse events, and the Euroqol EQ-5D questionnaire were assessed at day 28.  
 
 
Statistical analyses 
Based on our predicted sample size of 849 patients, we estimated the precision with 
which we would be able to detect a difference in the mean Rockall (19) score 
between treatment policies, which might indicate selection bias. Using a two-sided 
significance level of 5%, an intra-cluster correlation coefficient (ICC) of 0·033 and 
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standard deviation of 1·84, 849 participants would provide 92% power to detect a 
mean difference of one point (15). 
 
The statistical analysis plan was published before database lock (20). All analyses 
were pre-defined unless otherwise stated. Analyses were performed on all enrolled 
patients for whom an outcome was available. We also performed an analysis on all 
enrolled patients with a Hb below 120g/L during follow-up, as it was anticipated a 
priori this group was most likely to receive a transfusion and be affected by the 
treatment policy.  
 
Feasibility and clinical outcomes were analysed using cluster-level summaries, with 
equal weight given to each cluster (21-22). Results are presented as a difference in 
means for continuous outcomes, and a difference in proportions for binary outcomes. 
Pre-specified subgroup analyses and post-hoc analyses are listed in the web 
appendix (page 3). 
 
 
Role of the funding source 
The funder had no role in study design, data collection, data analysis, data 
interpretation or report writing. The writing committee had full access to all data and 
final responsibility to submit for publication. BCK and CJD are statistical guarantors.  
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Results: 
Screening and enrolment 
There were 1667 AUGIB admissions to the six hospitals during the recruitment period 
of whom 1600 of 1667 (96%) were eligible and 936 of 1660 (59%) enrolled (Figure 
1). Recruitment rate was significantly higher in the liberal policy (62% vs. 55%, 
p=0·04). Three percent were ineligible due to exsanguinating bleeding (19 of 896 
[2%] liberal arm vs. 33 of 771 [4%] restrictive arm; p=0·08). The commonest 
reason for non-enrolment was consent refusal for data collection and telephone 
follow up which occurred in 430 of 1600 (27%). Data on further bleeding were 
missing in no patients at hospital discharge, but in 31 of 936 (3%) at day 28 who 
were excluded from the analysis. Telephone contact at day 28 to administer an EQ-
5D questionnaire was not possible in 136 of 403 (34%) participants in the restrictive 
policy and 296 of 533 (56%) in the liberal policy. 
 
Baseline characteristics and selection bias 
Baseline characteristics were similar in terms of Rockall and Blatchford risk scores, 
blood pressure, heart rate, and symptoms of bleeding (Table 1 and web appendix 
Table 1). There were some baseline imbalances in co-morbidities with a greater 
proportion of patients in the liberal policy with liver disease (91 of 533 [17%] vs. 45 
of 403 [11%]) whereas more patients in the restrictive policy had respiratory disease 
(84 of 403 [21%] vs. 74 of 533 [14%]) or hypertension (123 of 403 [31%] vs. 109 
of 533 [20%]). The prevalence of ischaemic heart disease (IHD) was the same 
between treatment arms. Bleeding was due to peptic ulcer disease in 153 of 673 
(22%), erosive disease in 171 of 673 (25%) and gastro-oesophageal varices in 81 of 
673 (12%). In the liberal policy, patients enrolled were older than those not enrolled, 
compared to the restrictive policy, where patients enrolled were younger than those 
not enrolled (Table 2). 
 
Protocol adherence 
Overall adherence to the transfusion protocol (mean number of Hb counts with no 
deviations, per patient) was significantly higher in the restrictive policy (96%; sd 10) 
compared to the liberal policy (83%; sd 25; p= 0·005), with a similar pattern seen in 
patients with a Hb <120 g/L (restrictive policy 94% [sd 12] vs liberal policy 76% [sd 
27]; p=0·003) (Table 3). Adherence each month was consistent in the restrictive 
policy, but decreased in the liberal policy (Figure 2). In the liberal policy 675 of 2769 
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(24%) of all Hbs led to a protocol deviation (672 no transfusion administered when 
Hb<100 g/L; three transfusions administered when Hb>100 g/L), compared with 93 
of 1754 (5%) in the restrictive group (67 no transfusion administered when Hb<80 
g/L, 26 transfusions administered when Hb>80 g/L).  
 
Transfusion and Hb separation 
Amongst all patients, 247 of 533 (46%) were transfused in the liberal policy 
compared to 133 of 403 (33%) in the restrictive policy (difference -12%, 95% CI -35 
to 11, p=0·23). The mean number of units transfused was lower in the restrictive 
policy (1·2 units [sd 2·1] restrictive policy vs 1·9 units [sd 2·8] liberal policy; 
difference -0·7 units, 95% CI -1·6 to 0·3, p=0·12) (Table 3). In patients with a 
Hb<120 g/L the Hb at hospital discharge was significantly lower in the restrictive 
policy (101 g/L [sd 13] restrictive policy vs 107 g/L units [sd 12] liberal policy; 
difference -7 g/L, 95% CI -14 to 0·0, p=0·05) (Figure 3). In the cohort with a Hb 
<100 g/L, the mean Hb over the entire follow up period as well as at discharge was 
significantly lower in the restrictive policy compared to the liberal policy (Table 3). 
 
Clinical outcomes 
There were no significant differences in clinical outcomes or mean EQ-5D between 
treatment groups (Table 4). Further bleeding at 28 days (patients with Hb <120 g/L) 
occurred in 13 of 257 (5%) in the restrictive policy compared to 31 of 383 (9%) in 
the liberal policy (difference -3·7%; 95% CI -12·2 to 4·8%). Mortality at 28 days 
(patients with Hb <120 g/L) occurred in 14 of 257 (5%) in the restrictive policy 
compared to 25 of 383 (7%) in the liberal policy (difference -1·3%; 95% CI -8·0 to 
5·5%) (Table 4).).  
 
  
 
  11 
Discussion 
This is the first multi-centre randomised trial comparing transfusion strategies for 
AUGIB, gathering evidence for the feasibility of a phase 3 trial. The pragmatic 
eligibility criteria mean that 96% of participants were eligible, of whom almost 60% 
were enrolled. The cluster design was acceptable to clinicians, resulted in an efficient 
recruitment rate and facilitated implementation of the transfusion policy hospital-
wide, alongside routine clinical care. A high level of adherence to both transfusion 
policies was achieved, resulting in a 13% absolute reduction in the proportion of 
patients transfused in the restrictive policy, reduction in the amount of blood 
transfused between treatment policies and separation in Hb. The modest reduction in 
mean number of RBC units transfused was in keeping with that reported in a meta-
analysis of transfusion trigger trials (23). 
 
Protocol adherence was better in the restrictive policy where it was consistent 
throughout the trial. In the liberal policy most violations were due to not 
administering RBCs below the threshold of 100 g/L. This greater adherence to the 
restrictive policy may reflect clinician bias for lower transfusion thresholds for AUGIB, 
particularly for lower risk patients, extrapolated from evidence of the safety of more 
restrictive transfusion in trials of critical care,(5) cardiac surgery (4) and hip surgery 
(10). Our liberal threshold of 100 g/L was informed by actual UK transfusion practice 
at the time the study was designed. Guidelines advocating restrictive transfusion for 
AUGIB are based upon a single trial conducted in an intensive care population, where 
patients with acute bleeding were specifically excluded (5); transfusion requirements 
may reasonably be expected to differ after acute bleeding due to rapid development 
of anaemia and haemodynamic compromise. For the phase 3 trial, we plan to lower 
the threshold for transfusion in the liberal arm to reflect this changing practice and 
we would also exclude lower risk patients (Rockall score = 0) who are unlikely to be 
transfused.  
 
The greater adherence in the restrictive policy may also have been influenced by the 
Barcelona trial of transfusion strategies for gastrointestinal bleeding (14), published 
during recruitment to TRIGGER. In this single centre trial, improved survival and 
rebleeding rates were observed in patients transfused below 70 g/L, compared to 90 
g/L. Whether these results would be obtained in other hospitals particularly in the UK 
is questionable on several grounds. Firstly, a high proportion of the trial population 
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had liver cirrhosis and variceal bleeding; a treatment effect was only observed in 
these patients in whom mechanisms of bleeding differ and who account for only 
10% of UK presentations with AUGIB. Secondly, the trial excluded patients with 
major comorbidities including IHD, vascular disease or stroke which excludes almost 
40% of all UK presentations with AUGIB (24), representing the group at greatest 
potential of complications from acute anaemia. Thirdly, processes of care are unlikely 
to be reproducible at other institutions, specifically the delivery of therapeutic 
endoscopy to all patients within six hours, which may influence transfusion use. 
Furthermore, single centre trials tend to find larger treatment effects than multi-
centre trials (25), highlighting the risk of making strong recommendations based on 
a single centre trial (25-26).  
 
Despite some baseline imbalances, participants in each policy had similar risk scores 
and haemodynamic status. Participants enrolled in the liberal policy were older than 
those not enrolled, while in the restrictive arm those enrolled were younger than 
participants not enrolled. These are most likely chance imbalances due to the small 
number of clusters. For the main trial, approximately 30 clusters would need to be 
randomised and this is likely to achieve acceptable balance between treatment arms. 
Pre-specified covariate adjustment will also account for any unexpected baseline 
imbalances in important prognostic factors (27). It is possible that baseline 
imbalances were due to selection bias given the open-label nature of the study. 
Preventing selection bias will be important in the phase 3 trial. A potential solution is 
to seek consent waiver for anonymous data collection to allow routinely collected 
data to be summarised on all eligible participants.  
 
TRIGGER was not a phase 3 trial, so its clinical outcomes should not be used to 
directly inform clinical practice. A key area of uncertainty in transfusion practice 
concerns safe transfusion thresholds in patients with IHD (8, 10, 28), particularly 
relevant to AUGIB where 14% have IHD. A pilot trial of transfusion strategies in 
patients with IHD found a 15% absolute increase in mortality in patients receiving 
transfusion at a threshold of 80 g/L compared to 100 g/L (10), a similar magnitude 
of excess mortality as that observed in TRIGGER (web appendix page 4), highlighting 
the need for further evidence before advocating universal restrictive transfusion for 
AUGIB.  
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This feasibility trial provides key learning points for the design of the phase 3 trial. 
We plan to enrol the same patient population as in TRIGGER, using broad and 
inclusive eligibility criteria to promote efficient recruitment and generalisability, 
although we would exclude the lowest risk patients unlikely to be recipients of 
transfusion. For higher risk patients with IHD or cerebrovascular disease who may be 
particularly susceptible to adverse effects of anaemia, we would ask the Independent 
Data Monitoring Committee to monitor SAEs and provide recommendations at formal 
interim analysis about their continued enrolment, as well as conducting pre-specified 
subgroup analysis for IHD. Despite the results of the Barcelona trial (14), we would 
also enroll patients with liver cirrhosis, given the limitations of external validity in that 
trial. For the interventions, we plan to lower thresholds for transfusion to 90 g/L in 
the liberal arm and to 70 g/L in the restrictive arm which accounts for the area of 
uncertainty in current practice. Whilst previous transfusion strategy trials have used  
Hb level as an entry criterion (5, 6, 8, 14), we designed this trial to assess the impact 
of implementing a treatment policy on a hospital wide scale for all patients 
presenting with AUGIB, and would repeat this efficient design for a phase 3 trial, but  
additionally incorporate a pre-specified secondary analysis of clinical outcomes using 
the transfusion threshold in the liberal arm as a cut-off. 
 
The primary outcome for the phase 3 trial would be mortality. Our estimate of the 
ICC, essential for sample size calculation, was similar to that estimated from a UK 
audit of AUGIB, likely to reflect that both studies were pragmatic, recording all 
presentations with AUGIB. We would still randomise by cluster in order to evaluate 
the treatment effect of a policy in a diverse patient population in routine clinical care, 
whilst minimising contamination. These benefits far outweigh the commonly cited 
limitation of statistical inefficiency in cluster trials, particularly since sufficient 
recruitment would not be a barrier in this trial; we estimate that although 15% more 
participants would need to be recruited through cluster randomisation, recruitment 
time would be almost 40% less, resulting in a more efficient trial design (web 
appendix page 5). We believe this design offers an attractive method of conducting 
comparative effectiveness research in the NHS for treatment policies that are within 
the boundaries of normal care and where there is clinical equipoise. 
 
Participant consent for routine clinical data and telephone follow up was lower than 
anticipated. For the phase 3 trial we would seek consent waiver to enable analysis of 
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routinely recorded in-hospital data on all patients. The trial design would be more 
efficient through linkage to routine administrative data to record mortality and re-
admissions, which would also permit follow up to longer horizons. Telephone follow 
up at day 28 for patient reported outcomes would be replaced by an assessment of 
functional status at discharge to reduce attrition rates given difficulties in telephone 
contact. 
 
Reducing RBC transfusion for AUGIB would have significant financial implications for 
healthcare agencies. In 2013/14, 1.7 million units of RBCs were issued in England 
with an estimated 204,000 units for AUGIB alone, costing £123.31 per unit. A 13% 
reduction, as demonstrated in this trial, would lead to annual savings to the NHS of 
£3.3m for the blood alone, which excludes blood transfusion laboratory and blood 
administration costs. 
 
We used a pragmatic cluster randomised design to demonstrate the feasibility of 
implementing hospital wide transfusion policies for AUGIB, resulting in a reduction in 
blood use and separation in Hb. Conducting a large cluster-randomised phase 3 trial 
to assess the effectiveness of transfusion strategies for AUGIB is now essential 
before practice guidelines are changed to recommend restrictive transfusion for all 
patients with AUGIB. 
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PANEL: RESEARCH IN CONTEXT 
Systematic review: 
We conducted a Cochrane review of randomised controlled trials comparing red cell 
transfusion strategies for AUGIB in 2008 and updated this in 2010 (29). Three 
underpowered trials including a total of 93 participants were identified. The small 
number of participants, missing data and methodological deficiencies did not permit 
meaningful conclusions, justifying the need for a trial of transfusion strategies for 
AUGIB. One on-going single centre trial from Barcelona was identified which 
commenced in 2003 and was published in 2013 (14), half way through TRIGGER 
recruitment, which reported a reduction in mortality and rebleeding with restrictive 
transfusion and thus recommended restrictive transfusion for AUGIB. The population 
in the Barcelona trial differed since one-third had liver cirrhosis where the 
mechanism of bleeding differs, excluded patients with cardiovascular comorbidity and 
employed care processes unlikely to be generalisable to most healthcare institutions 
(3).  
 
 
Interpretation: 
The purpose of TRIGGER was to assess the feasibility and safety of implementing 
restrictive versus liberal transfusion strategies for AUGIB in UK hospitals using cluster 
randomisation to inform feasibility of a phase 3 trial. The randomised transfusion 
policies were successfully implemented on a hospital wide scale across multiple 
specialty groups and clinical areas for a six month period with a high level of protocol 
adherence, leading to a reduction in RBC exposure in the restrictive policy and 
separation in haemoglobin concentration between the treatment groups. No 
significant differences in clinical outcomes were observed, although the trial was not 
powered for this. If restrictive transfusion is proven to be safe and effective in a 
larger, similarly pragmatic trial design, this would have the potential to safely reduce 
the use of RBCs for the largest single indication for transfusion in England and may 
have broader implications for the more restrictive use of RBCs after acute 
haemorrhage. A larger cluster randomised trial is feasible and essential to conduct 
before clinical practice guidelines recommend restrictive transfusion for all patients 
with AUGIB. 
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Table 1: Baseline characteristics, Laboratory parameters and Co-
interventions 
 Liberal policy 
(n=533) 
Restrictive 
policy (n=403) 
Male – no. (%) 322 (60) 244 (61) 
Age (years) – mean (SD) 60·4 (20·0) 58·0 (20·3) 
Rockall score – median (IQR) 2 (1 to 4) 2 (1 to 4) 
Blatchford score – median (IQR) 6 (2 to 10) 6 (1 to 9) 
Signs and symptoms 
Melaena – no. (%) 266 (50) 209 (52) 
Haematemesis – no. (%) 302 (57) 209 (52) 
Heart rate (bpm) – mean (SD) 95·6 (20·1) 94·8 (21·8) 
Systolic blood pressure (mmHg) – mean (SD) 125·9 (22·7) 126·9 (22·8) 
Pre-existing co-morbidities n(%) 
Ischaemic heart disease  76 (14) 61 (15) 
Cardiac failure  21 (4) 18 (4) 
Hypertension  109 (20) 123 (31) 
Respiratory disease  74 (14) 84 (21) 
Renal disease  36 (7) 18 (4) 
Liver disease  91 (17) 45 (11) 
Malignancy  58 (11) 41 (10) 
Stroke  34 (6) 25 (6) 
First recorded laboratory data – mean (SD) 
Haemoglobin (g/L)  114 (34) 119 (32) 
Urea (mmol/L)  10·2 (7·2) 10·0 (7·6) 
Albumin (g/L)  36 (8) 38 (7) 
Lowest Hb during follow up (g/L) – no. (%) 
≤79 146 (27) 118 (29) 
80 - 99 146 (27) 69 (17) 
100 -120 91 (17) 70 (17) 
≥121 149 (28) 146 (36) 
Medications and fluids 
Proton pump inhibitor (pre endoscopy) – no. (%) 296 (60) 252 (63) 
Iron (oral or IV)* – no. (%) 47 (9) 43 (11) 
Any Intravenous fluids**– no. (%) 412 (81) 297 (75) 
Colloid volume in 24 hours – mean (SD) 0·2 (0·6) 0·1 (0·4) 
Crystalloid volume in 24 hours – mean (SD) 1·6 (1·4) 1·9 (1·7) 
Platelets – no. (%)*** 13 (2) 13 (3) 
Fresh frozen plasma – no. (%) 22 (4) 24 (6) 
Cryoprecipitate – no. (%) 1 (<1) 2 (1) 
Source of bleeding - no. (%) 
  Peptic ulcer 
  Gastro-oesophageal varix 
  Oesophagitis/gastritis/duodenitis 
  Mallory-Weiss tear 
  Malignancy 
  Non-identified 
  Other 
94 (24) 
56 (15) 
89 (23) 
8 (2) 
13 (3) 
60 (16) 
67 (17) 
59 (20) 
25 (8) 
82 (28) 
22 (8) 
9 (3) 
49 (17) 
40 (16) 
*Data missing in 24 patients liberal policy, 11 restrictive policy; **Data missing on 24 patients 
liberal policy, 8 restrictive policy;*** data missing in 9 cases liberal policy, 1 case restrictive 
policy for platelets/FFP/cryoprecipitate.  
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Table 2 – Differences between eligible patients who were enrolled vs. not enrolled  
 
Parameter Liberal policy Restrictive policy  
 Enrolled 
n=533 
Not-enrolled 
n=363 
Difference 
between 
enrolled vs. not-
enrolled 
Enrolled 
n=403 
Not-enrolled 
n=368 
Difference 
between 
enrolled vs. 
not-enrolled 
P-value for 
difference 
between treatment 
policies 
Age (years) 59·9 (20·0) 53·9 (23·4) 5.2 57·4 (20·3) 59·8 (23·6) -2.6 0·05 
Hb g/L 115 (34) 128 (31) -10 119 (32) 126 (27) -4·0 0·08 
Rockall 
score 
2·3 (1·8) 1·7 (1·9) 0.6 2·4 (2·1) 2·5 (1·9) -0·1 0·07 
Blatchford 
score 
6·1 (4·6) 3·8 (4·1) 2.4 5·8 (4·6) 4·7 (4·5) 1·3 0·07 
*All data presented as a mean (sd). In the liberal policy there were 533 patients enrolled vs. 363 not enrolled, and in the restrictive policy there were 403 
patients enrolled vs. 368 not enrolled.
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Table 3: Protocol adherence, RBC transfusion and Haemoglobin results† 
Outcome Liberal policy  Restrictive 
policy  
Treatment effect* 
(restrictive vs. 
liberal) and 95% CI 
P-
value 
 
All enrolled patients n=533 n=403   
Overall adherence %– mean (SD) ** 83 (25) 96 (10) 14 (7 to 21) 0·005 
Patients receiving at least one 
transfusion – no. (%) 
247 (46) 133 (33) -12 (-35 to 11) 0.23 
Number of units transfused – mean 
(SD) 
1·9 (2·8) 1·2 (2·1) -0·7 (-1·6 to 0·3) 0·12 
Mean Hb over entire follow-up period 
– mean (SD) 
115 (23) 115 (26) -1·0 (-12·0 to 11·0) 0·90 
Last recorded Hb – mean (SD) 118 (20) 116 (24) -2·0 (-12·0 to 7·0) 0·50 
Patients with Hb<120 g/L (n=383) (n=257)   
Overall adherence % – mean (SD) 76 (27) 94 (12) 19 (11 to 26) 0·003 
Patients receiving at least one 
transfusion – no· (%) 
246 (64) 132 (51) -12 (-36 to 12) 0·24 
Number of units transfused – mean 
(SD) 
2·6 (3·0) 1·8 (2·5) -0·8 (-1·9 to 0·3) 0·12 
Mean Hb over entire follow-up period 
– mean (SD) 
103 (13) 98 (15) -5·0 (-13·0 to 3·0) 0·18 
Last recorded Hb prior to discharge – 
mean (SD) 
107 (12) 101 (13) -7·0 (-14·0 to 0·0) 0·05 
Patients with Hb<100 g/L (n=293) (n=190)   
Overall adherence %– mean (SD) 69 (28) 93 (14) 24 (16 to 32) 0·001 
Patients receiving at least one 
transfusion – no. (%) 
242 (83) 130 (68) -14·3 (-32·2 to 3·6) 0·09 
Number of units transfused – mean 
(SD) 
3·4 (3·0) 2·4 (2·6) -1·0 (-2·0 to 0·01) 0·05 
Mean Hb over entire follow-up period 
– mean (SD) *** 
98 (10) 92 (10) -0·6 (-11·0 to -1·0) 0·02 
Last recorded Hb prior to discharge – 
mean (SD)**** 
105 (12) 96 (11) -9·0 (-14·0 to -4·0) 0·007 
*Treatment effects are difference in means for continuous outcomes, and a difference in 
percentage points for binary outcomes; **Overall adherence refers to the proportion of Hb 
counts where no deviation from the transfusion policy occurred for each patient; ***18 
patients had missing data and were excluded from this analysis (16 Liberal, 2 Restrictive); 
****50 patients had missing data and were excluded from this analysis (37 Liberal, 13 
Restrictive);  
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Table 4 – Clinical outcomes (patients with Hb < 120 g/L) 
Outcome Liberal policy 
(n=383) 
Restrictive 
policy (n=257) 
Treatment effect* 
(restrictive vs. 
liberal) and 95% CI 
Further bleeding – no. (%)    
          Day 28 31 (9) 13 (5) -3·7 (-12·2 to 4·8) 
          Hospital discharge 24 (6) 9 (4) -3·3 (-13·4 to 6·9) 
All-cause mortality – no. (%)    
          Day 28 25 (7) 14 (5) -1·3 (-8·0 to 5·5) 
Thromboembolic or ischaemic 
events – no. (%) 
   
          Day 28 23 (7) 9 (4) -3·5 (-9·9 to 3·0) 
          Hospital discharge 21 (5) 7 (3) -3·3 (-8·7 to 2·2) 
Surgical or radiological intervention – 
no. (%) 
   
          Hospital discharge 11 (3) 10 (4) 0·9 (-4·2 to 5·9) 
Acute transfusion reactions – no. (%)    
          Hospital discharge 9 (2) 2 (1) -1·6 (-3·6 to 0·5) 
Therapeutic intervention – no. (%)    
          At hospital discharge 144 (38) 81 (32) -7·1 (-25·1 to 10·9) 
Infections – no. (%)    
          At hospital discharge 92 (24) 67 (26) 0·8 (-25·3 to 26·9) 
Length of hospital stay (days) – 
median (IQR) 
   
           At hospital discharge 5 (3 to 9) 4 (3 to 7) -0·7 (-1·6 to 0·3) 
EQ-5D – mean (SD)    
          Day 28 0·69 (0·32) 0·76 (0·27) 0·07 (-0·10 to 0·23) 
Serious adverse events – no. (%)    
          Day 28 83 (22) 45 (18) -4.9 (-22·6 to 12·8) 
*Treatment effects are difference in means for continuous outcomes, and a difference in 
percentage points for binary outcomes;  
Missing data: 27 patients had missing data for further bleeding and were excluded from this 
analysis (19 Liberal, 8 Restrictive); 1 patient was missing day 28 mortality in the liberal arm 
and excluded from this analysis; 48 patients were missing data on thromboembolic/ischaemic 
events at day 28 and excluded from this analysis (33 liberal, 15 restrictive); 5 patients were 
missing data on acute transfusion reactions and excluded from this analysis (3 liberal, 2 
restrictive); 31 patients missing information on length of stay and excluded from this analysis 
(21 liberal, 10 restrictive); 295 patients missing information on EQ-5D at day 28 and excluded 
from this analysis (214 liberal, 81 restrictive); 1 patient in the liberal arm missing data on 
SAEs in the liberal arm and excluded from this analysis. 
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Figure 1 –Trial schema 
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Figure 2 – Overall adherence to the transfusion policy by study month (patients 
with haemoglobin concentration of less than120 g/L) 
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Figure 3 – Mean haemoglobin concentration over time (patients with 
haemoglobin concentration of less than120 g/L) 
  22 
Contributors:  
VJ – study conception and design, interpretation of data, drafting of manuscript, 
approval of final version 
BCK – study design, analysis and interpretation of data, drafting of manuscript, 
approval of final version 
AG - study design, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
CJD - study design, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
AM – Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
MWJ - Acquisition of data, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
AJS - Acquisition of data, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
SME - Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
AAB – Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
HD - Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
JG- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
ILJ- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
MD- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
NC- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
IR- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
RH- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
CD- Acquisition of data, revision of manuscript for important intellectual content, 
approval of final version  
  23 
SM- study design, revision of manuscript for important intellectual content, approval 
of final version  
CL - study design, revision of manuscript for important intellectual content, approval 
of final version  
KRP- study design, revision of manuscript for important intellectual content, approval 
of final version  
RFL- study design, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
SPT- study design, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
TSW- study design, interpretation of data, revision of manuscript for important 
intellectual content, approval of final version  
MFM- study conception and design, interpretation of data revision of manuscript for 
important intellectual content, approval of final version  
 
 
 
TRIGGER trial collaboration: 
Trial Management Group: Vipul Jairath, Mike Murphy, Brennan Kahan, Martin James, 
Alasdair Gray, Tim Walsh, Elizabeth Stokes, Adrian Stanley, Claire Dyer, Ana Mora, 
Renate Hodge, Charlotte Llewelyn. 
 
Independent Data Monitoring Committee: Michael Greaves (Chair), Bob Walt, Marc 
Turner, Keith Wheatley  
 
Trial Steering Committee: Chris Hawkey (chair), Duncan Wyncoll, Jonathan Benger, 
Tim Walsh, Richard Logan, Caroline Doré, Helen Campbell, Cliff Gorton 
(Independent, lay member), Sarah Meredith, Charlotte Llewelyn. 
 
  24 
Participating hospitals and personnel (number of patients enrolled) 
Royal Infirmary of Edinburgh, Edinburgh (201): Alasdair Gray, Nick Church, Lynn 
Mason, James Dear, Kallirroi Keffala, Rachel O’Brien, Alison Glover.  
 
Queen’s Medical Centre, Nottingham (191): Martin James, Ivan Le Jeune, Lisa 
Mannion, Rachel Foster. 
 
Glasgow Royal Infirmary, Glasgow (188): Adrian Stanley, Aidan Cahill, Ewan Forrest, 
John Morris, Jack Winter, Neil Jamieson, Dan Gaya, Stephen Barclay, Neil Dignon, 
Scott Taylor, Allan Cameron, Dr Ruth Gillespie, Rosalind Boyle, Susan Thornton, 
Janet Johnston. 
 
St James’s University Hospital, Leeds (154): Simon Everett, Pradeep Mundre, Saqib 
Muntaz, Ruth Fazakerley, Sally Fox. 
 
John Radcliffe Hospital, Oxford (111): Adam Bailey, Sian Davies, Sally Beer, Ian 
Reckless, Melanie Darwent, Rebecca Palmer, James East. 
 
James Cook University Hospital, Middlesbrough (91): Helen Dallal, John Greenaway , 
Diamond Joy, Julie McGivern, Marie Branch.  
 
Conflicts of interest: We declare that we have no conflicts of interest. 
 
Acknowledgments: The project was funded by NHS Blood and Transplant 
Research and Development (grant number 10-09-CSU) and run by NHSBT Clinical 
Trials Unit (formerly NHSBT/ MRC Clinical Trials Unit). The sponsors of the study 
played no part in the preparation of this article. The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of NHS Blood 
and Transplant. The trial benefited from the support provided by the NIHR Clinical 
Research Networks. We thank the independent members of the TSC and the IDMC, 
members of the lay focus group and patient panel who inputted into the trial design 
and Age UK Abingdon for allowing us to conduct a focus group with members of the 
public. We thank all clinical teams in participating centres for their support and 
following the transfusion policies. 
 
  25 
 
REFERENCES: 
1. Crooks C, Card T, West J. Reductions in 28-day mortality following 
hospital admission for upper gastrointestinal hemorrhage. Gastroenterology. 
2011;141:62-70. 
2. Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP. Ten-
year pattern of red blood cell use in the North of England. Transfusion. 2013 
Mar;53(3):483-9. 
3. Jairath V. Acute upper gastrointestinal bleeding--time for some new 
triggers? Transfus Med. 2013 Jun;23(3):139-41. 
4. Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, 
et al. Transfusion requirements after cardiac surgery: the TRACS randomized 
controlled trial. JAMA. 2010 Oct 13;304(14):1559-67. 
5. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello 
G, et al. A multicenter, randomized, controlled clinical trial of transfusion 
requirements in critical care. Transfusion Requirements in Critical Care 
Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999 Feb 
11;340(6):409-17. 
6. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads 
GG, et al. Liberal or restrictive transfusion in high-risk patients after hip 
surgery. N Engl J Med. 2011 Dec 29;365(26):2453-62. 
7. Walsh TS, Wyncoll DL, Stanworth SJ. Managing anaemia in critically ill 
adults. BMJ. 2010;341:c4408. 
8. Walsh TS, Boyd JA, Watson D, Hope D, Lewis S, Krishan A, et al. 
Restrictive versus liberal transfusion strategies for older mechanically 
ventilated critically ill patients: a randomized pilot trial. Crit Care Med. 2013 
Oct;41(10):2354-63. 
9. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman 
SA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma 
and critical care. Crit Care Med. 2009 Dec;37(12):3124-57. 
10. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, 
et al. Liberal versus restrictive transfusion thresholds for patients with 
symptomatic coronary artery disease. Am Heart J. 2013 Jun;165(6):964-71 
e1. 
11. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal 
upper gastrointestinal bleeding. Gastroenterology. 2013 Jun;144(7):1384-93, 
93 e1-2; quiz e18-9. 
12. Hearnshaw SA, Logan RF, Palmer KR, Card TR, Travis SP, Murphy 
MF. Outcomes following early red blood cell transfusion in acute upper 
gastrointestinal bleeding. Aliment Pharmacol Ther. 2010 Jul;32(2):215-24. 
13. Restellini S, Kherad O, Jairath V, Martel M, Barkun AN. Red blood cell 
transfusion is associated with increased rebleeding in patients with 
nonvariceal upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2012 
Dec 3. 
14. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, 
Aracil C, et al. Transfusion strategies for acute upper gastrointestinal 
bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21. 
15. Jairath V, Kahan BC, Gray A, Dore CJ, Mora A, Dyer C, et al. 
Restrictive vs liberal blood transfusion for acute upper gastrointestinal 
  26 
bleeding: rationale and protocol for a cluster randomized feasibility trial. 
Transfus Med Rev. 2013 Jul;27(3):146-53. 
16. http://www.nhsbt.nhs.uk/trigger/documents/study-
protocol/TRIGGER_%20Protocol.pdf. 2012. 
17. Barkun AN. International consensus recommendations on the 
management of patients with nonvariceal upper gastrointestinal bleeding. Ann 
Intern Med. 2010;152:101-13. 
18. de Franchis R. Revising consensus in portal hypertension: report of the 
Baveno V consensus workshop on methodology of diagnosis and therapy in 
portal hypertension. J Hepatol. 2010 Oct;53(4):762-8. 
19. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment 
after acute upper gastrointestinal haemorrhage. Gut. 1996 Mar;38(3):316-21. 
20. Kahan BC, Jairath V, Murphy MF, Dore CJ. Update on the transfusion 
in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a 
cluster-randomised feasibility trial. Trials. 2013;14:206. 
21. Donner A KN. Design and Analysis of Cluster Randomization Trials in 
Health Research. New York: Oxford University Press Inc; 2000. 
22. Hayes RJ ML. Cluster Randomised Trials. Boca Raton, FL: Chapman 
& Hall/CRC. 2009. 
23. Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. 
Transfusion thresholds and other strategies for guiding allogeneic red blood 
cell transfusion. Cochrane Database Syst Rev. 2010(10):CD002042. 
24. UK Comparative Audit of Upper Gastrointestinal Bleeding and the Use 
of Blood. British Society of Gastroenterology. [Accessed at 
www.bsg.org.uk/pdf_word_docs/blood_audit_report_07.pdf]. 2007. 
25. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-
center trials show larger treatment effects than multicenter trials: evidence 
from a meta-epidemiologic study. Ann Intern Med. 2011 Jul 5;155(1):39-51. 
26. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-
center trials. Crit Care Med. 2009 Dec;37(12):3114-9. 
27. Kahan BC, Jairath V, Dore CJ, Morris TP. The risks and rewards of 
covariate adjustment in randomized trials: an assessment of 12 outcomes 
from 8 studies. Trials. 2014;15:139. 
28. Jairath V, Kahan BC, Logan RF, Travis SP, Palmer KR, Murphy MF. 
Red blood cell transfusion practice in patients presenting with acute upper 
gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion. 2011 
Sep;51(9):1940-8. 
29. Jairath V, Hearnshaw S, Brunskill SJ, Doree C, Hopewell S, Hyde C, et 
al. Red cell transfusion for the management of upper gastrointestinal 
haemorrhage. Cochrane Database Syst Rev. 2010(9):CD006613. 
 
 
 
  27 
Supplementary Appendix 
 
Guidance criteria used to define ineligibility due to exsanguinating bleeding 
 
 
1. The patient was prescribed emergency O-negative blood 
2. The patient had features of shock (defined as systolic blood pressure <100 
mm/Hg and/or heart rate >100 beats per minute) AND was transfused red 
blood cells within 2 hours of presentation 
3. The first endoscopy was performed in the emergency department, HDU/ICU   
(or equivalent) or operating theatre due to severity of bleeding. 
 
Definition of AUGIB 
Haematemesis or the passage of melaena 
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Table 1: Additional Baseline Characteristics of the patients enrolled 
 Liberal arm 
(n=533) 
Restrictive arm 
(n=403) 
Time since onset of GI bleed symptoms - 
no. (%) 
  
     <12 hours  274 (52) 154 (38) 
     12-24 hours 94 (18) 82 (20) 
     >24 hours  152 (29) 145 (36) 
     Not known  12 (2) 22 (5) 
Rockall score – median (IQR) 2 (1 to 4) 2 (1 to 4) 
Blatchford score – median (IQR) 6 (2 to 10) 6 (1 to 9) 
Signs and symptoms 
Fresh blood per rectum – no. (%) 25 (5) 26 (6) 
Syncope – no. (%) 42 (8) 36 (9) 
Coffee-ground vomitus – no. (%) 135 (25) 157 (39) 
First recorded vital signs 
Heart rate (bpm) – mean (SD) 95·6 (20·1) 94·8 (21·8) 
Temperature (Celsius) – mean (SD) 36·6 (07·) 36·5 (0·9) 
Oxygen saturation (%) – mean (SD) 97·5 (2·2) 97·4 (2·6) 
Systolic blood pressure (mmHg) – mean (SD) 125·9 (22·7) 126·9 (22·8) 
Respiratory rate (breaths/minute) – mean (SD) 17·7 (3·6) 18·2 (3·9) 
First recorded laboratory data 
Haemoglobin (g/dL) – mean (SD) 114 (34) 119 (32) 
Platelet count (x109L) – mean (SD) 259·2 (121·6) 264·2 (129·4) 
INR (seconds) – median (IQR) 1·0 (0·9 to 1·2) 1·0 (0·9 to 1·2) 
PT (seconds) – median (IQR) 12 (11 to 13) 13 (12 to 15) 
APTT (seconds) – mean (SD) 29·0 (7·1) 30·6 (12·6) 
Fibrinogen (g/L) – mean (SD) 3·6 (0·9) 3·3 (1·1) 
Sodium (mmol/L) – mean (SD) 138 (4) 138 (4) 
Potassium (mmol/L) – mean (SD) 43 (0·6) 4·1 (0·7) 
Urea (mmol/L) – mean (SD) 10·2 (7·2) 10·0 (7·6) 
Creatinine (mmol/L) – mean (SD) 91 (52) 89 (47) 
Albumin (g/L) – mean (SD) 36 (8) 38 (7) 
Bilirubin (umol/L) – median (IQR) 11 (7 to 20) 10 (6 to 17) 
Alkaline Phosphatase (IU/L) – median (IQR) 112 (75 to 185) 93 (68 to 158) 
Alkanine Transaminase (IU/L) – median (IQR) 23 (16 to 38) 20 (13 to 35) 
Regular medication prior to admission 
Dipyridamole – no. (%) 1 (<1) 1 (<1) 
Selective serotonin re-uptake inhibitor – no. (%) 43 (8) 30 (7) 
Proton pump inhibitor – no. (%) 193 (36) 100 (25) 
Low molecular weight heparin – no. (%) 5 (1) 9 (2) 
 
 
Care processes 
Overall 45 of 482 (9%) of patients in the trial received endoscopy within 6 hours of 
presentation and 298 of 482 (62%) within 24 hours. More patients in the liberal 
policy received therapeutic endoscopy compared to the restrictive policy (149 of 533 
[28%] vs. 85 of 403 [21%]). Transfusion of platelets, fresh frozen plasma and 
cryoprecipitate was similar between policies. 
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Other clinical outcomes 
There were no significant differences in any clinical outcomes between the two 
groups. Thromboembolic or ischaemic events were reported in nine of 257 (4%) in 
the restrictive policy compared to 23 of 383 (7%) in the liberal policy (difference -
3·5%; 95% CI -9·9 to 3·0%). Serious adverse events were reported in 45 of 257 
(18)% the restrictive policy compared to 83 of 383 (22%) the liberal policy 
(difference -4·9%; 95% CI -22·6 to 12·8%. In patients with ischaemic heart disease, 
death was reported in 6 of 49 cases (12%) in the restrictive policy compared to 2 of 
67 cases (3%) in the liberal policy (difference 10·7%, 95% CI -9·8 to 31·2; 
interaction p=0·11). 
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 Table 2: Clinical outcomes – post-hoc adjusted analyses* (Hb<12) 
Outcome Liberal 
policy 
(n=383) 
Restrictive 
policy 
(n=257) 
Treatment 
effect** 
(restrictive vs. 
liberal) and 
95% CI 
Further bleeding     
          Day 28 31 (9) 13 (5) -3·6 (-8·7 to 
1·5) 
          Hospital 
discharge 
24 (6) 9 (4) -3·0 (-8·7 to 
2·8) 
All-cause mortality     
          Day 28 25 (7) 14 (5) 0·6 (-3·3 to 4·5) 
Thromboembolic or 
ischaemic events  
   
          Day 28 23 (7) 9 (4) -2·0 (-6·2 to 
2·2) 
          Hospital 
discharge 
21 (5) 7 (3) -1·8 (-5·2 to 
1·6) 
Surgical or 
radiological 
intervention  
   
          Hospital 
discharge 
11 (3) 10 (4) 0·8 (-3·0 to 4·6) 
Acute transfusion 
reactions  
   
          Hospital 
discharge 
9 (2) 2 (1) -1·1 (-2·5 to 
0·4) 
Therapeutic 
intervention  
   
          At hospital 
discharge 
144 (38) 81 (32) -5·4 (-14·1 to 
3·2) 
Infections     
          Day 28 92 (24) 67 (26) 4·0 (-28·5 to 
36·5) 
Length of hospital 
stay (days)  
5 (3 to 9) 4 (3 to 7) -1·0 (-2·7 to 
0·6) 
    
EQ-5D     
          Day 28 0·69 (0·32) 0·76 (0·27) 0·02 (-0·13 to 
0·18) 
Serious adverse 
events  
   
          Day 28 83 (22) 45 (18) -2·9 (-13·8 to 
8·1) 
*Analyses are adjusted for age, heart rate, systolic blood pressure, respiratory rate, 
Hb, time since onset of symptoms, haematemesis, suspected active bleeding, 
syncope, suspected shock, ischaemic heart disease, respiratory disease renal 
disease, liver disease, cancer, PPI, and coagulation 
**Treatment effects are difference in means for continuous outcomes, and a 
difference in percentage points for binary outcomes. 
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Table 3: Presumed cause of death up to day 28 (all patients) 
 Liberal arm 
(n=26 
deaths) 
Restrictive 
arm (n=16 
deaths) 
Presumed cause of 
death – no. (%) 
  
          Cardiac failure 2 (8) 1 (7) 
          Liver failure 4 (15) 1 (7) 
          Malignancy 6 (23) 2 (13) 
          Multi-organ failure 1 (4) 0 (0) 
          Other 8 (31) 5 (33) 
          Respiratory failure 2 (8) 1 (7) 
          Uncontrolled 
bleeding 
2 (8) 1 (7) 
          Unknown 1 (4) 4 (27) 
 
Pre-specified adjusted analyses 
Main analyses were unadjusted for baseline covariates, however a pre-specified 
secondary analysis for clinical outcomes was performed after adjustment for age, 
shock, coagulopathy, and the number of major co-morbidities. Mean imputation was 
used to account for missing baseline covariates, and age and the number of major 
co-morbidities were modelled using fractional polynomials.  
 
Pre-specified subgroup analyses conducted 
Pre-specified subgroup analyses were performed using an interaction test for further 
bleeding and all-cause mortality at day 28 for presence vs. absence of ischaemic 
heart disease and for variceal vs. non-variceal bleeding 
 
Post-hoc analyses conducted 
Analyses conducted post-hoc were: (a) adherence, Hb, and transfusion outcomes on 
patients with a recorded Hb below 100 g/L; (b) adherence outcomes on patients with 
variceal bleeding and (c) clinical outcomes adjusting for more baseline covariates to 
account for imbalances 
 
Full list of baseline covariates adjusted for 
Age, heart rate, systolic blood pressure, respiratory rate, Hb, time since onset of 
symptoms, haematemesis, suspected active bleeding, syncope, suspected shock, 
ischaemic heart disease, respiratory disease renal disease, liver disease, cancer, use 
of proton pump inhibitors and presence of coagulopathy (INR>1.5). 
 
Updated estimates of the ICC 
The updated ICC estimate from these trial data were calculated as 0.026 for further 
bleeding and 0.001 for mortality. These were almost identical to the estimates from 
observational data before the trial was conducted (0.027 for further bleeding and 
0.001 for mortality) (15).  
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Table 4: Subgroup analyses (patients with Hb < 12) 
Outcome Subgroup Liberal arm – 
no. (%) with 
outcome 
Restrictive arm 
– no. (%) with 
outcome 
Treatment effect* 
(restrictive vs. 
liberal) and 95% CI 
P-value for 
interaction 
Ischaemic heart disease 
Further 
bleeding 
No 25/298 (8) 10/203 (5) -3·9 (-12·1 to 4·4) 0·85 
Yes 6/66 (9) 3/46 (7) -2·7 (-20·8 to 
15·4) 
Mortality No 23/315 (7) 8/208 (4) -3.2 (-8·4 to 1·9) 0·11 
Yes 2/67 (3) 6/49 (12) 10·7 (-9·8 to 31·2) 
Variceal bleeding** 
Further 
bleeding 
No 23/259 (9) 9/195 (5) -4·5 (-9·2 to 0·3) 0·73 
Yes 7/51 (14) 4/22 (18) 0·7 (-40·2 to 41·6) 
Mortality No 12/268 (4) 10/198 (5) 0·4 (-7·1 to 8·0) 0·18 
Yes 6/55 (11) 1/23 (4) -7·1 (-20·3 to 6·0) 
*Treatment effects are difference in percentage points 
**263 patients were missing information on whether they experienced variceal 
bleeding, and were excluded from the analysis 
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Design features of the proposed main trial based upon learning points from TRIGGER 
Population 
Inclusion criteria: All new adults presenting with AUGIB, defined of haematemesis or 
passage of melaena. 
 
Exclusion criteria: Patients with exsanguinating bleeding; those with a Rockall score 
of zero at presentation to hospital; existing in-patients who develop bleeding. 
 
Interventions 
Restrictive transfusion policy: Eligible for transfusion if Hb <70 g/L, with a post-
transfusion target of 70-90 g/L 
 
Liberal transfusion policy: Eligible for transfusion if Hb < 90 g/L, with a post-
transfusion target of 90-110 g/L 
 
As per the feasibility study, the timing and frequency of Hb measurements, as well 
as the number of units transfused, will not be protocolised. This will enhance the 
generalisability of the study and the relevance to routine clinical care. 
 
Outcomes  
Primary outcome: Mortality within 28 days after presentation. Cause specific 
mortality will also be recorded. 
Mortality and hospital re-admission data will also be sought 12 months after 
enrolment. For deaths, NHS information centre service will be used to identify the 
date and cause of death. For re-admissions the NHS Information Centre Trusted 
Data Linkage service will be used to provide a data-set of patients linked to Hospital 
Episode Statistics dataset, to include reasons for admission, diagnoses and 
procedures. 
 
Secondary outcomes will be further bleeding; need for therapeutic intervention; 
thromboembolic/ischaemic events; infections; transfusion reactions; length of stay; 
functional status using the Katz Index of Independence in Activities in Daily living at 
discharge from hospital or in-hospital at 28 days after enrolment (bathing, dressing, 
toileting, transferring, continence and feeding); patient status at 12 months (death, 
hospital admission). 
 
Study design  
Parallel group, cluster randomised trial, without matching or stratification.  
 
Sample size comparisons between an individually randomised vs. cluster randomised 
trial 
To detect a difference in mortality of 7% vs. 4.5% between treatment groups with 
90% power and a two-sided 5% significance level, an individually randomised trial 
would require 3642 patients. A cluster-randomised trial with 30 clusters and an 
intraclass correlation coefficient of 0.001 would require approximately 4200 patients 
(a 15% increase). Assuming that 40 eligible patients present to each month to each 
of the 30 centres (based upon feasibility trial results), and that 40% of eligible 
patients are enrolled in an individually randomised trial compared to 75% for a 
cluster randomised trial, an individually randomised trial would complete recruitment 
in 7.6 months, compared to 4.7 months for a cluster randomised trial (a 38% 
reduction). These figures do not account for staggered site set up and total trial 
duration. 
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Pre-specified subgroup analyses and rationale: 
1. Patients with ischaemic heart disease. There is uncertainty as to the optimal 
management of anaemia in this subgroup, who may be particularly 
susceptible to the effect of anaemia. 
2. Patients with liver cirrhosis and variceal bleeding. Portal hypertensive 
bleeding has a different aetiology and mechanism of bleeding; this group may 
be particularly susceptible to the effects of volume overload so assessing a 
treatment effect in this subgroup is important and has biological plausibility 
3. Age of blood: mortality (the primary endpoint) in patients transfused blood 
<7 days of age versus those receiving blood >7 days of age. There is some 
evidence to suggest harmful effects of older blood, so again a biological 
plausible subgroup. 
 
 
Advantages and disadvantages of randomising by cluster for the main trial 
 
Advantages 
1. Assess the population level impact of implementing a treatment policy in 
routine clinical care, which is more useful to patients, clinicians, and 
healthcare agencies.  
2. Ensures a majority of eligible patients are enrolled which enhances the 
generalisibilty of the results. This is in contrast with previous individually 
randomised transfusion trials, where as few as 15% of eligible participants 
are have been enrolled. 
3. This is a trial of an acute medical emergency where an intervention has to be 
implemented immediately at the “front door” and then be maintained as the 
patient moves across several clinical areas and clinical teams in a short space 
of time. Cluster randomisation ensures that all hospital personnel will be 
aware of the transfusion policy and can implement it for every patient 
admitted with AUGIB, ultimately reducing contamination between two 
differing treatment polices in the same hospital. 
 
Disadvantages 
1. Statistical inefficiency and the need for a greater number of patients to be 
enrolled compared to an individual patient randomised trial. However, we 
have demonstrated from the rapid recruitment in TRIGGER that recruitment 
of sufficient participants would not be a limiting factor in this trial. 
2. The need for an accurate estimate of the ICC to inform sample size 
considerations. For the main trial we now have estimates both from the pilot 
and observational audit, which concur. 
3. Lack of blinding as all personnel in a cluster (hospital) would be aware of the 
transfusion policy, which could lead to biases in outcome reporting, 
particularly for more subjective outcomes. For the main trial we are using an 
objective primary endpoint (mortality), so assessment of this endpoint would 
not be influenced by lack of blinding. 
 
